Recommendations for Benchmarking Preclinical Studies of Nanomedicines.

ABSTRACT: Nanoparticle-based delivery systems provide new opportunities to overcome the limitations associated with traditional small-molecule drug therapy for cancer and to achieve both therapeutic and diagnostic functions in the same platform. Preclinical trials are generally designed to assess therapeutic potential and not to optimize the design of the delivery platform. Consequently, progress in developing design rules for cancer nanomedicines has been slow, hindering progress in the field. Despite the large number of preclinical trials, several factors restrict comparison and benchmarking of different platforms, including variability in experimental design, reporting of results, and the lack of quantitative data. To solve this problem, we review the variables involved in the design of preclinic

SUBMITTER: Dawidczyk CM 

PROVIDER: S-EPMC4592474 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature